Journal article
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial
Abstract
BACKGROUND: Doravirine is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) with a pharmacokinetic profile supporting once-daily dosing, and potent in-vitro activity against the most common NNRTI-resistant HIV-1 variants. We compared doravirine with ritonavir-boosted darunavir, when both were given with two nucleoside reverse transcriptase inhibitors (NRTIs), in adults with previously untreated HIV-1 infection.
METHODS: In this …
Authors
Molina J-M; Squires K; Sax PE; Cahn P; Lombaard J; DeJesus E; Lai M-T; Xu X; Rodgers A; Lupinacci L
Journal
The Lancet HIV, Vol. 5, No. 5, pp. e211–e220
Publisher
Elsevier
Publication Date
May 2018
DOI
10.1016/s2352-3018(18)30021-3
ISSN
2352-3018